Hypercalcemia of malignancy: An update on pathogenesis and management
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Hypercalcemia of malignancy is a common finding typically found in patients with advanced stage cancers. We aimed to provide an updated review on the etiology, pathogenesis, clinical presentation, and management of malignancy-related hypercalcemia. We searched PubMed/Medline, Scopus, Embase, and Web of Science for original articles, case reports, and case series articles focused on hypercalcemia of malignancy published from 1950 to December 2014. Hypercalcemia of malignancy usually presents with markedly elevated calcium levels and therefore, usually severely symptomatic. Several major mechanisms are responsible for the development of hypercalcemia of malignancy including parathyroid hormone-related peptide-mediated humoral hypercalcemia, osteolytic metastases-related hypercalcemia, 1,25 Vitamin D-mediated hypercalcemia, and parathyroid hormone-mediated hypercalcemia in patients with parathyroid carcinoma and extra parathyroid cancers. Diagnosis should include the history and physical examination as well as measurement of the above mediators of hypercalcemia. Management includes hydration, calcitonin, bisphosphonates, denosumab, and in certain patients, prednisone and cinacalcet. Patients with advanced underlying kidney disease and refractory severe hypercalcemia should be considered for hemodialysis. Hematology or oncology and palliative care specialists should be involved early to guide the options of cancer targeted therapies and help the patients and their closed ones with the discussion of comfort-oriented care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoclast differentiation and activation
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670 · cited 1×
“[12-14] In conclusion, the intricate interaction between calcium levels, PTH, Vitamin D, and bone cells regulates bone metabolism and calcium release from the bones.”
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Clinical Implications of the Osteoprotegerin/RANKL/RANK System for Bone and Vascular Diseases
Hofbauer, L. C. (2004) · JAMA · doi:10.1001/jama.292.4.490 · Cited by 988
Hypercalcemia Associated with Cancer
Stewart, A. F. (2005) · New England Journal of Medicine · doi:10.1056/nejmcp042806 · Cited by 973
Major, P., Lortholary, A., Hon, J., Abdi, E., Mills, G., Menssen, H. D., Yunus, F., Bell, R., Body, J., Quebe-Fehling, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.558 · Cited by 858
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women
Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W. J., Lacey, D. L., & Riggs, B. L. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17215 · Cited by 825 · cited 1×
“Factors that exert the opposite effects on bone turnover (such as estrogens) stimulate the release of osteoprotegerin from osteoblasts, binding RANKL, and preventing it from binding to RANK on the osteoclast precursor cell.[12-14]”
Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors
Gasparyan, A. Y., Ayvazyan, L., Blackmore, H., & Kitas, G. D. (2011) · Rheumatology International · doi:10.1007/s00296-011-1999-3 · Cited by 694
Molecular aspects of tumor cell invasion and metastasis
Aznavoorian, S. A., Murphy, A. N., Stetler‐Stevenson, W. G., & Liotta, L. A. (1993) · Cancer · doi:10.1002/1097-0142(19930215)71:4<1309::aid-cncr2820710423>3.0.co;2-m · Cited by 459
Calcitonin: Physiology and Pathophysiology
Austin, L. A., & Heath, H. (1981) · New England Journal of Medicine · doi:10.1056/nejm198101293040505 · Cited by 420
Bisphosphonates: An Update on Mechanisms of Action and How These Relate to Clinical Efficacy
RUSSELL, R. G. G., XIA, Z., DUNFORD, J. E., OPPERMANN, U., KWAASI, A., HULLEY, P. A., KAVANAGH, K. L., TRIFFITT, J. T., LUNDY, M. W., PHIPPS, R. J., et al. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1402.089 · Cited by 391
Denosumab: mechanism of action and clinical outcomes
Hanley, D. A., Adachi, J. D., Bell, A., & Brown, V. (2012) · International Journal of Clinical Practice · doi:10.1111/ijcp.12022 · Cited by 377
Mechanisms of intestinal calcium absorption
Bronner, F. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10330 · Cited by 308
Pathogenesis of myeloma bone disease
Roodman, G. D. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22403 · Cited by 296
Electrocardiographic manifestations: electrolyte abnormalities
Diercks, D. B., Shumaik, G. M., Harrigan, R. A., Brady, W. J., & Chan, T. C. (2004) · The Journal of Emergency Medicine · doi:10.1016/j.jemermed.2004.04.006 · Cited by 293
Parathyroid Hormone-Related Protein: An Update
Wysolmerski, J. J. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2142 · Cited by 279
Cinacalcet Hydrochloride Reduces the Serum Calcium Concentration in Inoperable Parathyroid Carcinoma
Silverberg, S. J., Rubin, M. R., Faiman, C., Peacock, M., Shoback, D. M., Smallridge, R. C., Schwanauer, L. E., Olson, K. A., Klassen, P., & Bilezikian, J. P. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0585 · Cited by 274
Corticosteroid-induced clinical adverse events: frequency, risk factors and patient?s opinion
Fardet, L., Flahault, A., Kettaneh, A., Tiev, K. P., Généreau, T., Tolédano, C., Lebbé, C., & Cabane, J. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.07950.x · Cited by 273
Denosumab for Treatment of Hypercalcemia of Malignancy
Hu, M. I., Glezerman, I. G., Leboulleux, S., Insogna, K., Gucalp, R., Misiorowski, W., Yu, B., Zorsky, P., Tosi, D., Bessudo, A., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1001 · Cited by 203
Johnson, R. W., Nguyen, M. P., Padalecki, S. S., Grubbs, B. G., Merkel, A. R., Oyajobi, B. O., Matrisian, L. M., Mundy, G. R., & Sterling, J. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2993 · Cited by 197
Treatment of Hypercalcemia Secondary to Parathyroid Carcinoma with a Novel Calcimimetic Agent
Collins, M. T. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.4.1083 · Cited by 194
Warrell, R. P., ISRAEL, R., FRISONE, M., SNYDER, T., GAYNOR, J. J., & BOCKMAN, R. S. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-5-669 · Cited by 163
Biology of breast cancer bone metastasis
Akhtari, M., Mansuri, J., Newman, K. A., Guise, T. M., & Seth, P. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.1.5163 · Cited by 160
Rehydration in the Treatment of Severe Hypercalcaemia
Hosking, D. J., Cowley, A. J., & BUCKNALL, C. A. (1981) · QJM · doi:10.1093/oxfordjournals.qjmed.a067700 · Cited by 128
Mellis, D. J., Itzstein, C., Helfrich, M. H., & Crockett, J. C. (2011) · Journal of Endocrinology · doi:10.1530/joe-11-0212 · Cited by 112
Vitamin D Metabolite-Mediated Hypercalcemia
Adams, J. S. (1989) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30365-7 · Cited by 94
Pecherstorfer, M., Steinhauer, E. U., Rizzoli, R., Wetterwald, M., & Bergstr�m, B. (2003) · Supportive Care in Cancer · doi:10.1007/s00520-003-0477-1 · Cited by 93
Investigation of hypercalcemia
Endres, D. B. (2012) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.04.025 · Cited by 91
Salmon calcitonin in the acute management of hypercalcemia
Wisneski, L. A. (1990) · Calcified Tissue International · doi:10.1007/bf02553290 · Cited by 86
Xu, X., Gou, W.-L., Wang, Y., Wang, Y., Guo, Q., Lu, Q., Lu, S., & Peng, J. C. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-303 · Cited by 79
Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients
Pecherstorfer, M., Schilling, T., BLIND, E., Zimmer-Roth, I., Baumgartner, G., Ziegler, R., & Raue, F. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.78.5.8175989 · Cited by 78
Safety of pamidronate in patients with renal failure and hypercalcemia.
Machado, C., & Flombaum, C. D. (1996) · PubMed · Cited by 77
Gucalp, R. A., Theriault, R., Gill, I., Madajewicz, S., Chapman, R., Navari, R., Ahmann, F., Zelenakas, K., Heffernan, M., & Knight, R. D. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.1994.00420170079008 · Cited by 74
Denosumab for Prevention of Fractures in Postmenopausal Women With Osteoporosis
Cummings, S. R., Martín, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P. D., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000363236.41902.96 · Cited by 63
Cicci, J. D., Buie, L. W., Bates, J. S., & van Deventer, H. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.07.005 · Cited by 49
Ventricular fibrillation in hypercalcaemic crisis due to primary hyperparathyroidism.
Kiewiet, R. M., Ponssen, H., Janssens, E. N. W., & FELS, P. W. (2004) · PubMed · Cited by 47
Survival in hypercalcaemic patients with cancer and co-existing primary hyperparathyroidism
Hutchesson, A. C. J., Bundred, N. J., & RATCLIFFE, W. A. (1995) · Postgraduate Medical Journal · doi:10.1136/pgmj.71.831.28 · Cited by 44
Bilezikian, J. P. (2012) · Endocrine Practice · doi:10.4158/ep12166.ra · Cited by 39
ST segment elevation mimicking acute myocardial infarction in hypercalcaemia
Turhan, S., Kılıçkap, M., & Kilinc, S. (2005) · Heart · doi:10.1136/hrt.2003.030874 · Cited by 22
A Case of Multiple Myeloma Coexisting with Primary Hyperparathyroidism and Review of the Literature
Hussain, N., Khan, M., Natarajan, A., Mohammedabdul, M., Mustafa, U., Yedulla, K., & Mirrakhimov, A. E. (2013) · Case Reports in Oncological Medicine · doi:10.1155/2013/420565 · Cited by 13
Self-citation
Cited by
The essential metals for humans: a brief overview
Zoroddu, M. A., Aaseth, J., Crisponi, G., Medici, S., Peana, M., & Nurchi, V. M. (2019) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2019.03.013 · Cited by 1,085
Nicolatou-Galitis, O., Schiødt, M., Mendes, R. A., Ripamonti, C., Hope, S., Drudge-Coates, L., Niepel, D., & Van den Wyngaert, T. (2019) · Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2018.09.008 · Cited by 361
Metadata
- Authors
- Mirrakhimov, A.
- Venue
- North American Journal of Medical Sciences
- Publisher
- Medknow
- Published
- 2015
- Volume
- 7
- Issue
- 11
- Pages
- 483
- ISSN
- 1947-2714 (ISSN-L)
- OpenAlex
- W2173934737
- Cited by
- 290
- References
- 39
- FWCI
- 7.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.